Insider Selling: SiBone (NASDAQ:SIBN) Director Sells 18,759 Shares of Stock

SiBone (NASDAQ:SIBN) Director Jeffrey Dunn sold 18,759 shares of the stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $19.33, for a total value of $362,611.47. Following the sale, the director owned 110,115 shares in the company, valued at approximately $2,128,522.95. This trade represents a 14.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

SiBone Price Performance

SIBN traded down $0.29 during trading on Thursday, hitting $18.50. The company’s stock had a trading volume of 46,182 shares, compared to its average volume of 448,258. The company has a quick ratio of 6.62, a current ratio of 7.97 and a debt-to-equity ratio of 0.21. The stock has a market capitalization of $802.67 million, a price-to-earnings ratio of -36.26 and a beta of 0.76. The firm’s 50 day moving average price is $16.81 and its two-hundred day moving average price is $16.83. SiBone has a 12 month low of $12.49 and a 12 month high of $20.05.

SiBone (NASDAQ:SIBN) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SiBone had a negative return on equity of 12.86% and a negative net margin of 11.24%.The business had revenue of $48.66 million during the quarter, compared to analysts’ expectations of $46.67 million. Sell-side analysts forecast that SiBone will post -0.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

SIBN has been the topic of several research analyst reports. Morgan Stanley increased their price target on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Truist Financial decreased their price target on SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, October 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of SiBone in a research report on Monday. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, SiBone currently has an average rating of “Moderate Buy” and a consensus price target of $23.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. State of Alaska Department of Revenue bought a new stake in SiBone in the third quarter valued at about $39,000. State of Wyoming bought a new position in SiBone during the second quarter worth about $55,000. Canada Pension Plan Investment Board acquired a new position in shares of SiBone during the 2nd quarter worth about $68,000. Virtus Advisers LLC bought a new stake in shares of SiBone in the 1st quarter valued at about $58,000. Finally, Quarry LP raised its position in shares of SiBone by 862.6% in the 3rd quarter. Quarry LP now owns 4,861 shares of the company’s stock valued at $72,000 after acquiring an additional 4,356 shares during the period. 98.11% of the stock is currently owned by institutional investors.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.